C07D221/06

BENZOQUINOLONE INHIBITORS OF VMAT2
20170246159 · 2017-08-31 ·

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

BENZOQUINOLONE INHIBITORS OF VMAT2
20170246159 · 2017-08-31 ·

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

Compositions of protein receptor tyrosine kinase inhibitors
09738659 · 2017-08-22 · ·

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

Compositions of protein receptor tyrosine kinase inhibitors
09738659 · 2017-08-22 · ·

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

Heterocyclic compound, and organic light-emitting device using same

The present application provides a hetero-cyclic compound capable of significantly enhancing lifespan, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device containing the hetero-cyclic compound in an organic compound layer.

Heterocyclic compound, and organic light-emitting device using same

The present application provides a hetero-cyclic compound capable of significantly enhancing lifespan, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device containing the hetero-cyclic compound in an organic compound layer.

Compound, OLED display panel and display device

The present disclosure relates to the field of organic electroluminescence materials and particularly relates to a compound, an OLED display panel and a display device. The compound according to the present disclosure has a structure represented by a formula (I) or a formula (II): ##STR00001##

Heterocyclic compound and organic light emitting device using same

The present application provides a hetero-cyclic compound capable of significantly enhancing lifespan, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device containing the hetero-cyclic compound in an organic compound layer.

Heterocyclic compound and organic light emitting device using same

The present application provides a hetero-cyclic compound capable of significantly enhancing lifespan, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device containing the hetero-cyclic compound in an organic compound layer.

Process for the preparation of cycloheptapyridine CGRP receptor antagonists

The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process. ##STR00001##